Streetbeat News

Analyst Ratings

SNOW

JP Morgan analyst Mark Murphy has maintained an Overweight rating on Snowflake (NYSE:SNOW) and raised the price target from $155 to $180.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 12:39 pm

HCA

Barclays analyst Steve Valiquette has maintained an Equal-Weight rating on HCA Healthcare (NYSE:HCA) and raised the price target from $275 to $300.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 12:39 pm

BKNG

Wedbush analyst Scott Devitt has reiterated an 'Outperform' rating on Booking Holdings (NASDAQ:BKNG) and maintained a price target of $3060.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 12:37 pm

CLRB

Cellectar Biosciences, Inc. (NASDAQ:CLRB) presented interim data from its ongoing study of iopofosine I 131 in multiple myeloma at the SNMMI Annual Meeting. The data showed an overall response rate of 28%, a clinical benefit rate of 70%, and a disease control rate of 92% in 64 evaluable patients. The company's COO, Jarrod Longcor, highlighted the outcomes from two dose levels across these highly refractory patients. The FDA has granted Fast Track and Orphan Drug Designations for iopofosine in patients with r/r MM.

Portfolio Pulse from Happy Mohamed

June 28, 2023 | 12:37 pm

SNOW

Wedbush analyst Taz Koujalgi has reiterated a Neutral rating on Snowflake (NYSE:SNOW) and maintained a price target of $144.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 12:35 pm

CCI

HOOD

LMT

Richard Saperstein of HighTower Treasury Partners recommended Lockheed Martin Corporation (LMT) due to its 5.5% free cash flow yield. Jenny Harrington of Gilman Hill Asset Management recommended Crown Castle Inc. (CCI) due to its 5.5% yield and expected growth. Josh Brown of Ritholtz Wealth Management mentioned Robinhood Markets, Inc. (HOOD) due to its recent layoffs. CCI reported Q1 revenues of $1.77 billion, beating consensus. Robinhood is cutting about 7% of its full-time staff due to reduced customer engagement.

Portfolio Pulse from Lisa Levin

June 28, 2023 | 12:34 pm

TMHC

Wedbush analyst Jay McCanless maintains an Outperform rating on Taylor Morrison Home (NYSE:TMHC) and raises the price target from $45 to $61.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 12:34 pm

CCS

Wedbush analyst Jay McCanless has maintained an Outperform rating on Century Communities (NYSE:CCS) and raised the price target from $70 to $89.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 12:33 pm

FUSN

Wedbush analyst David Nierengarten has reiterated an Outperform rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and maintained a $13 price target.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 12:32 pm

NFLX

Oppenheimer analyst Jason Helfstein maintains an Outperform rating on Netflix (NASDAQ:NFLX) and raises the price target from $450 to $500.

Portfolio Pulse from richadhand@benzinga.com

June 28, 2023 | 12:31 pm